EMPAGLIFLOZIN Pharmacologic Class Indexing
- Class set ID
- 3bde06ff-1593-4ace-a167-a9137510fbfd
- Version
- 2
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | Cardinal Health 107, LLC | 20260217 | 13 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | Boehringer Ingelheim Pharmaceuticals, Inc. | 20260130 | 31 |
| These highlights do not include all the information needed to use SYNJARDY and SYNJARDY XR safely and effectively. See full prescribing information for SYNJARDY and SYNJARDY XR. SYNJARDY ® (empagliflozin and metformin hydrochloride tablets), for oral use SYNJARDY ® XR (empagliflozin and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2015 | Boehringer Ingelheim Pharmaceuticals, Inc. | 20260130 | 22 |
| These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY ® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | 20260130 | 10 |
| These highlights do not include all the information needed to use GLYXAMBI safely and effectively. See full prescribing information for GLYXAMBI. GLYXAMBI ® (empagliflozin and linagliptin tablets), for oral use Initial U.S. Approval: 2015 | Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim Pharma GmbH and Co. KG | Sixarp, LLC | Rottendorf Pharma GmbH | 20260120 | 23 |
| These highlights do not include all the information needed to use SYNJARDY and SYNJARDY XR safely and effectively. See full prescribing information for SYNJARDY and SYNJARDY XR. SYNJARDY ® (empagliflozin and metformin hydrochloride tablets), for oral use SYNJARDY ® XR (empagliflozin and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2015 | Boehringer Ingelheim Pharmaceuticals, Inc. | 20260120 | 17 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014 | Aphena Pharma Solutions - Tennessee, LLC | 20251027 | 4 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | Aphena Pharma Solutions - Tennessee, LLC | 20250421 | 1 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | A-S Medication Solutions | 20230808 | 11 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | A-S Medication Solutions | 20230724 | 9 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | A-S Medication Solutions | 20230503 | 1 |
| These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE ® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 | A-S Medication Solutions | 20230503 | 1 |